Tea consumption modulates hepatic drug metabolizing enzymes in Wistar rats

P P Maliakal1, P F Coville, S Wanwimolruk

  • 1School of Pharmacy, University of Otago, Dunedin, New Zealand.

Insights

Green tea consumption significantly boosted hepatic cytochrome P450 (CYP) 1A2 activity in rats. This suggests tea

Area of Science:

  • Pharmacology and Toxicology
  • Nutritional Science
  • Biochemistry

Background:

  • Green tea and its polyphenols exhibit antioxidant, antimutagenic, and anticarcinogenic properties.
  • Hepatic metabolizing enzymes are crucial for bioactivation of precarcinogens and detoxification of ultimate carcinogens.
  • Understanding tea's modulation of these enzymes is key to assessing cancer risk.

Purpose of the Study:

  • To investigate how tea consumption affects hepatic metabolizing enzyme activities in rats.
  • To determine the impact of different types of green and black tea on specific enzyme isoforms.
  • To explore the balance between Phase I and Phase II enzymes following tea intake.

Main Methods:

  • Female Wistar rats were administered aqueous solutions of six different teas or a green tea extract for four weeks.
  • Control group received water.
  • Liver microsomes and cytosols were analyzed for cytochrome P450 (CYP) isoform and phase II enzyme activities.

Main Results:

  • All tea treatments significantly increased CYP 1A2 activity.
  • CYP 1A1 activity increased in most groups, with exceptions.
  • Glutathione-S-transferase activity was significantly elevated by certain green teas.

Conclusions:

  • Tea consumption, particularly green tea, can modulate hepatic enzyme activities involved in carcinogen metabolism.
  • The observed increase in CYP 1A2 suggests enhanced detoxification pathways.
  • The balance between carcinogen-activating and detoxifying enzymes is influenced by tea intake, potentially impacting chemically-induced cancer risk.

Related Concept Videos

Hepatic Drug Excretion: Influencing Factors01:16

Hepatic Drug Excretion: Influencing Factors

The biliary system of the liver, crucial for bile secretion and drug excretion, comprises intrahepatic bile ducts that merge to form the common hepatic duct. This duct, carrying hepatic bile, combines with the cystic duct, draining the gallbladder and forming the common bile duct, which empties into the duodenum. Bile, produced by hepatic cells lining the bile canaliculi, is composed primarily of water, bile salts, pigments, electrolytes, and lesser amounts of cholesterol and fatty acids. Bile...
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...
Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug01:14

Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug

In pharmacotherapy, monitoring drug concentrations is paramount, especially for drugs whose therapeutic effects hinge on both the active compound and its metabolite. Hepatic impairment profoundly influences drug potency by altering liver function. If the drug is more potent than its metabolite, impaired liver function amplifies drug activity due to elevated drug concentration levels. Conversely, if the metabolite holds greater potency, diminished liver function diminishes drug activity by...
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...